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ABSTRACT
Purpose: Hyperthermia (40–44 C) effectively sensitises tumours to radiotherapy by locally altering
tumour biology. One of the effects of heat at the cellular level is inhibition of DNA repair by homolo-
gous recombination via degradation of the BRCA2-protein. This suggests that hyperthermia can expand
the group of patients that benefit from PARP-inhibitors, a drug exploiting homologous recombination
deficiency. Here, we explore whether the molecular mechanisms that cause heat-mediated degradation
of BRCA2 are conserved in cell lines from various origins and, most importantly, whether, BRCA2 pro-
tein levels can be attenuated by heat in freshly biopted human tumours.
Experimental design: Cells from four established cell lines and from freshly biopsied material of cer-
vical (15), head- and neck (9) or bladder tumours (27) were heated to 42 C for 60min ex vivo. In vivo
hyperthermia was studied by taking two biopsies of the same breast or cervical tumour: one before
and one after treatment. BRCA2 protein levels were measured by immunoblotting.
Results: We found decreased BRCA2-levels after hyperthermia in all established cell lines and in 91%
of all tumours treated ex vivo. For tumours treated with hyperthermia in vivo, technical issues and
intra-tumour heterogeneity prevented obtaining interpretable results.
Conclusions: This study demonstrates that heat-mediated degradation of BRCA2 occurs in tumour
material directly derived from patients. Although BRCA2-degradation may not be a practical biomarker
for heat deposition in situ, it does suggest that application of hyperthermia could be an effective
method to expand the patient group that could benefit from PARP-inhibitors.
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Introduction
Hyperthermia is an anti-cancer therapy that increases efficacy
of radiation therapy and of several chemotherapeutic agents
[1,2]. During hyperthermia treatment, external applicators are
positioned in such a way that the temperature of the tumour
is elevated to 40–44 C. Hyperthermia application devices
have been designed to heat various tumour types in a local-
ised fashion. A broad range of tumours can be treated with
hyperthermia including, but not limited to, those occurring
in the breast [3,4], cervix [5,6], head and neck [7,8], and blad-
der [9–11], resulting in growing interest for using hyperther-
mia as a means to increase the effectiveness and specificity
of cancer treatment while minimising side-effects [12].
Hyperthermia sensitises tumour cells to radiation and
chemotherapy by altering tumour biology, both at the
physiological and molecular level [13,14]. The most well-
investigated and well-known physiological effects of hyper-
thermia are the increase in local blood flow and the altera-
tions in vascular permeability, and the change in tumour
microenvironment [14,15]. Another physiological effect of
hyperthermia that has recently gained more attention is the
activation of the immune response by heat [16,17]. On the
molecular level, hyperthermia induces membrane stress and
it causes protein structures to unfold. All effects of hyperther-
mia are very dependent on the temperature reached in the
tumour and the duration of the treatment. For example,
most proteins remain relatively stable with temperatures in a
near-physiological range (<42 C) [18]. However, one known
exception is the protein BRCA2, which is degraded at tem-
peratures as low as 41 C [19].
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BRCA2 is an essential player in the DNA repair pathway
homologous recombination (HR). This DNA repair pathway is
employed by cells to aid in the repair of numerous aberrant
DNA structures or DNA lesions [20]. A prime example of a
complicated lesion that can be repaired through HR is a DNA
double strand break. Once a DNA double strand break has
occurred in one chromatid, HR taps into the information on
the undamaged sister chromatid to repair the break, thereby
ensuring faithful restoration. The necessity for the presence
of a sister chromatid, limits HR to the S- and G2-phases of
the cell cycle [20]. The main driver proteins of HR are RAD51
and its mediator BRCA2 [21]. Absence of the BRCA2-protein
abrogates HR by causing defects in RAD51 loading onto the
processed end(s) of the DNA double strand break [22,23].
By degrading BRCA2 in tumour cells, hyperthermia attenu-
ates HR and creates a temporary window for DNA damage to
persist, which is one of the explanations for how it sensitises to
DNA-damaging anti-cancer treatments, such as radiation ther-
apy and chemotherapy [19]. Likewise, tumours that harbour a
heritable BRCA2-mutation resulting in a dysfunctional BRCA2-
protein also lack functional HR, causing the tumours to be very
sensitive to a specific type of drugs: PARP-inhibitors [24,25].
PARP-inhibitors target the PARP-1 (Poly [ADP-ribose]
Polymerase 1) protein, which is involved in repair of single
strand DNA breaks. When PARP-1 is not available to repair
these DNA breaks, the single strand lesions are converted to
double strand breaks during DNA replication. These replica-
tion-induced DNA double strand breaks are extremely toxic to
cells, and have to be repaired via the HR-pathway in order for
cells to survive [26]. This explains why HR-defective tumours
are extremely sensitive to PARP-inhibitors, while they are
much less toxic to HR-proficient cells [24,25]. This results in
PARP-inhibitors being excellent precision medicine to treat
patients with HR-deficient cancers, because the patients them-
selves will experience minimal side-effects, while the tumour is
very sensitive to the drug. Recent approvals of two variants of
PARP-inhibitors (Olaparib/Lynparza, AstraZeneca and
Rucaparib, Clovis) for treatment of BRCA-mutated ovarian
tumours by the FDA demonstrate the popularity and effectivity
of this type of anti-cancer approach [27].
Although this precision treatment method is very elegant,
one inherent drawback is the small group of patients that are
eligible for these drugs, because a BRCA-mutation is rare [28].
By inducing temporary HR-deficiency in tumours in a local
fashion, hyperthermia could have the potential to enlarge the
patient group that might benefit from PARP-inhibitors, irre-
spective of their BRCA gene status. However, it is unknown
whether the molecular mechanisms present in established
tumour cell lines, and necessary for hyperthermia-mediated
degradation of BRCA2, are also functioning in primary tumour
tissue. Therefore, we explore hyperthermia’s ability to degrade
BRCA2 in primary tumour material of tumours that can clinic-
ally be heated, as a proof-of-concept study and as a first step
towards application of PARP-inhibitors and hyperthermia in a
clinical setting. Moreover, because the currently available heat-
ing techniques in vivo harbour large variability in heating pat-
terns and their quality assurance is challenging, we also
explore the possibility to use BRCA2 degradation in tumours as
a biomarker for the effectivity of hyperthermia.
Materials and methods
Cell culture
HeLa, FaDu, T24 and MDA-MB-231 were cultured as previ-
ously described [19].
Tumour collection (ex vivo study)
The effects of hyperthermia on BRCA2 protein levels were
studied in tumour material by subjecting collected biopsies
to heat ex vivo. All described specimens were obtained
between August 2012 and December 2016 within the
Erasmus MC Cancer Institute, Rotterdam (MEC 2017.234). All
tumours included in this study were leftover tissues after
pathological reviews, and could therefore be used for
research according to the “Code Proper Secondary Use of
Human Tissue”, founded by the Dutch Federation of Medical
Societies (www.fmwv.nl). All patients were informed by letter
that they might refuse the use of leftover tissue for research
purposes, in an opt-out manner. Tumour tissue specimens
were anonymised by coding, so that they could not be
traced back to individual patients.
Fresh cervical tumour tissue was taken with a biopsy for-
ceps from patients with locally advanced cervical carcinoma
(FIGO stage IIB-IVA) or recurrent disease, undergoing pelvic
examination under anaesthesia. All head and neck specimens
were primary tumours originating from the tongue and
obtained during COMMANDO-surgery. Bladder specimens of
both primary and recurrent tumours were collected during
transurethral resection procedures.
Tumour collection and hyperthermia treatment (in vivo
studies)
The study was continued by investigating BRCA2 protein lev-
els in biopsies of breast and cervical tumours taken before
and after clinical application of hyperthermia (in vivo). In the
first study (MEC 2012.559) we aimed to include 12 patients
who had local recurrent breast cancer without distant meta-
stases for whom treatment with superficial hyperthermia was
feasible. Patients with a BRCA1 or BRCA2 germline mutation
were excluded from this study. The biopsies were taken with
a 4-mm cutter from a previously irradiated area, right before
and directly after an extra hyperthermia session before the
start of the combined treatment. The study-related hyper-
thermia treatment was limited to one 433MHz Lucite cone
applicator [29] for superficial hyperthermia and given for
30min. Due to technical problems, the study was closed after
inclusion of five biopsy sets originating from four patients.
For the second study (MEC 2014.469) we aimed to include
16 patients with locally advanced cervical carcinoma that
underwent hyperthermia as part of their primary treatment.
The included patients were treated with hyperthermia
according to the standard treatment protocol with the BSD-
2000 3D system (Pyrexar Medical Systems, Salt Lake City, UT).
If possible, the first biopsy was taken during the examination
under anaesthesia, approximately four weeks before the start
of the treatment, to reduce patient burden. To prevent
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radiotherapy-induced alterations of tumours included in this
study, the sequence of the first radiotherapy and hyperther-
mia combination was altered: before the patient received the
first radiotherapy fraction, the second biopsy was taken after
one hour hyperthermia treatment (excluding pre-heating
time). The remaining four hyperthermia treatments of the
treatment cycle were delivered directly after radiotherapy.
The patients in these two studies were recruited between
July 2013 and May 2016, and a written informed consent
was obtained from all patients.
Tumour dissociation and ex vivo hyperthermia
treatment
Tumour biopsies were first transferred to the Department of
Pathology, for inspection by a pathologist. After analysis,
remaining material was transported to the laboratory in RPMI
medium (Sigma-Aldrich, St. Louis, MO), supplemented with
penicillin/streptomycin. The material was processed immedi-
ately upon arrival, and macroscopically visible blood vessels
and fat were removed. The tumour was manually cut into
small pieces (1mm3). The samples were then homogenised
using a human Tumour Dissociation kit and corresponding
protocol (Miltenyi Biotec, Bergisch Gladbag, Germany). Cells
in the homogenised mixture from tumours collected within
the context of the in vivo study were lysed immediately,
while cells from tumours in the ex vivo study were treated as
described in Figure 2.
Cell lysis
Cells were lysed as previously described [19]. Prior to lysis, the
cell suspension from tumour material was harvested by centri-
fuging (5min, 300 rcf, 4 C). The pellet then washed twice by
resuspension in cold PBS supplemented with 5mM EDTA and
subsequent centrifugation. If necessary, blood was removed
from the pellet by resuspension and subsequent incubation
for 2min at room temperature in ACK buffer (150mM NH4Cl,
10mM KHCO3, 0.1mM Na2EDTA, pH 7.3), after which the sam-
ple was centrifuged and washed once more with cold PBS.
Following the last centrifugation step, the pellet was resus-
pended in an appropriate amount of PBS, supplemented with
5mM EDTA, 2.5x cOmpleteTM Protease Inhibitor cocktail
(Roche, Basel, Switzerland) and 1mg/ml PefablocVR SC (Sigma-
Aldrich, St Louis, MO).
Immunoblotting procedure
After determining protein concentration in the samples using
a Lowry assay [30], 50–75 lg of the tumour lysate was loaded
and run on a 3–8% gradient Tris-Act gel (Novex, Thermo Fisher
Scientific, Waltham, MA). The separated proteins were blotted
on a PVDF membrane in a tank containing transfer buffer
(0.4M Glycine, 5mM Tris, 20% methanol) at a constant rate of
300mA for two hours at 4 C. The membrane was horizontally
cut into three separate pieces, which were blocked for at least
one hour in 3% milk in PBS-T (0.05% Tween). The primary anti-
bodies, BRCA2 (1:1000, OP95, Calbiochem, San Diego, CA),
PARP-1 (1:5000, Alexis/Enzo, Farmingdale, NY) and Origin repli-
cation complex 2 (ORC2) (1:1000, BD Pharmingen, San Diego,
CA), were diluted in PBS-T with 3% milk and incubated over-
night at 4 C. Blots were washed in PBS-T and incubated with a
secondary antibody (Sheep-anti-mouse HRP conjugated
1:2000; Jackson Immunoresearch, Suffolk, UK) for two hours at
room temperature. The signal was detected in an Alliance
(Uvitec Cambridge, Cleaver Scientific, Warwickshire, UK) at sev-
eral exposure times. The signal was detected by enhancing the
signal with ECL (Amersham; GE Life Sciences, Chicago, IL), but
if the BRCA2 signal proved too weak to detect, an enhanced
version of ECL (Supernova, Cyanagen, Bologna, Italy or Pierce,
Thermo Fisher Scientific, Waltham, MA) was used. In the pres-
entation of the blots, an asterisk indicates that the detected
signals were enhanced by changing the shadows-value from 0
to 175 in the “levels adjustment” tool in Photoshop (CS6,
Adobe). This adjustment was necessary for a clear impression
of the relative signal intensities.
Blot quantification
Antibody signals on the immunoblot were quantified using
the FIJI [31] “analyze gels” tool. To minimalize saturation of
the quantified signals, different exposure times were ana-
lysed. The BRCA2 signals were normalised to ORC2 to correct
for unequal loading, with notable exception of one bladder
tumour where we did not find ORC2 expression and used
PARP-1 instead. In the figures, the 42 C signal is always
expressed as a percentage of the matched 37 C control.
Results
Mild hyperthermia induces BRCA2 degradation in
various established cell lines
We started our proof-of-concept study by testing whether
hyperthermia induces BRCA2 degradation in established cell
lines of various origins. The selected cell lines, HeLa (cervix),
FaDu (head and neck), T24 (bladder), and MDA-MB-231
(breast), correspond to tumour types that are routinely treated
with hyperthermia in the Erasmus MC Cancer Institute. After
60min of effective hyperthermia, the cells were lysed, immu-
noblotted and the intensity of the BRCA2-signal was analysed.
BRCA2
PARP-1
MDA-MB-231
Breast
HeLa
Cervix
T24
Bladder
FaDu
Head and Neck
28%26% 34%29%
42°C37°C 42°C37°C42°C37°C42°C37°C
Figure 1. BRCA2 degradation in established cell lines of various tumour origins.
Immunoblots of cells without treatment (37 C) or treated with hyperthermia
(42 C) for 60min effectively, excluding 15min of pre-heating time. Upper row
of the panels show the BRCA2-signal, the lower panel shows the PARP-1-signal.
Each panel represents a set samples from a different cell line, from left to right:
HeLa (cervical), FaDu (head- and neck), T24 (bladder) and MDA-MB-231 (breast).
Percentages at the bottom of each panel indicate the relative intensity of the
BRCA2 signal (corrected to PARP-1) in the heat-treated sample compared to the
non-treated sample.
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We observed that in all cell lines employed the BRCA2-signal
was markedly decreased by treatment with 42 C (Figure 1),
demonstrating that hyperthermia is able to degrade BRCA2 in
multiple tumour cell lines.
Hyperthermia-induced BRCA2 degradation in primary
material
We extended our study by analysing BRCA2 degradation
upon hyperthermia in fresh tumour material. We collected
tumours from different sites that are treated with mild hyper-
thermia: cervix (15), head and neck (9) and bladder (27). The
tumours were directly transported to the laboratory, dissoci-
ated upon arrival and the resulting suspension was divided
in two aliquots: one aliquot was incubated ex vivo at 37 C
and the other at 42 C for 75min total. We then lysed the
cells, analysed the resulting samples by immunoblot and
subsequently quantified the BRCA2-signals, when possible
(Figure 2). Because we were not always able to prevent load-
ing differences between the two samples of the same
tumour, we normalised the BRCA2-signals to the ORC2-signal
in the same sample. We then expressed the normalised
BRCA2-signal in the hyperthermia-treated sample as a per-
centage of that in the untreated sample.
The loading difference was mainly caused by the relatively
mild nature of the employed dissociation method and the
differences in tumour structure, sometimes resulting in
incomplete homogenisation of the tumour samples. Even
though we used the Lowry protein assay to determine the
total protein content in the lysates and corrected for the
amount measured, loading differences within the same
tumour set could not always be prevented. When necessary,
we re-ran samples, by adjusting the amount loaded based
on the previous obtained result. However, this was not
always possible, because relative to the size of the samples
obtained, a significant amount of material is needed to
detect BRCA2 on a Western blot. To solve this, we normalised
the signal to ORC2, its signal intensity being comparable to
that of BRCA2. For one bladder tumour we used the PARP-1
signal to normalise, because no ORC2-signal could be
detected (marked with  in Figure 3C).
Due to technical issues during dissociation or immuno-
blotting, not all tumours included could be analysed, but we
were able to obtain results of 11 out of 15 cervical tumours,
five out of nine head- and neck tumours and 16 out of 27
collected bladder tumours. In the cervical tumours we
detected degradation of BRCA2 in all ex vivo treated samples,
the residual BRCA2-levels varying between 8% and 66%
(Figure 3(A)). In the head and neck tumours, we found
BRCA2 degradation in four samples (33–59% remaining levels
after 42 C), but hyperthermia did not result in degradation
of the BRCA2 protein in the fifth (Figure 3(B)). In material
obtained from bladder tumours, hyperthermia degraded
BRCA2 in 14 samples (20–79% residual protein levels), but in
two samples we found no clear alteration of BRCA2-protein
levels upon heat treatment (Figure 3(C)).
BRCA2 degradation as a biomarker for heat deposition
Next, we checked if BRCA2 degradation in biopsy material
can be used as a biomarker for effectivity of hyperthermia
[4,32,33]. To this end, two pilot studies were set up in which
we investigated BRCA2 protein levels in biopsies of recurrent
breast and primary cervical tumours that were taken before
and directly after clinical treatment with mild hyperthermia.
In the first pilot study, we included a total of four patients
with local recurrent breast cancer without distant metastases,
of which one patient was included twice. The biopsies we
tested were taken from previously irradiated areas of the
tumour, as only patients with these lesions have a standard
indication for treatment with hyperthermia. Moreover, super-
ficial hyperthermia elicits higher temperatures, has a more
homogeneous heating pattern and is less demanding for
patients, compared to deep hyperthermia [3,6].
Unfortunately, we found that the dissociation of the biopsies
60 min
Figure 2. Schematic representation of tumour collection. Fresh biopsies
obtained are dissociated enzymatically and mechanically. Dissociated suspen-
sions of tumours collected were prepared for treatment by centrifugation
(5min, 300 rcf) and subsequent resuspension in RMPI supplemented with 10%
FCS. The resulting cell suspension was divided over two separate culture dishes:
one was incubated at 37 C for 75min in a controlled environment (37 C, 5%
CO2, 20% O2), while the other was incubated at 42 C in a similarly controlled
environment for the same amount of time, allowing 15min to pre-heat the
medium and thus resulting in 60min of effective heating. After the treatment,
cells in both samples are lysed and the proteins are analysed on an
immunoblot.
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obtained from these areas was insufficient, in contrast to our
previous experiences with primary biopsies. These difficulties
might be caused by macroscopic changes in the extracellular
matrix and tumour structure in the re-irradiated areas. Owing
to the insufficient dissociation, we were only able to detect a
BRCA2-signal on the immunoblot in the biopsy material from
two patients, and never in both biopsies from the same
patient (Figure 4(A)). Because the technical problems in this
patient group prevented us from investigating the effect of
clinically applied hyperthermia on the BRCA2-protein levels
in the tumours, we decided to terminate this study.
In the second pilot study, we included six patients with
locally advanced cervical tumours, who are treated with a
combination treatment of hyperthermia and radiotherapy as
a standard of care [6]. In all biopsies tested, we were able to
detect BRCA2 (Figure 4(B)). We compared the BRCA2 signal
of the two biopsies taken before and directly after the end
of the hyperthermia to examine the effects of in vivo hyper-
thermia and found: (1) lower BRCA2-levels post-hyperthermia
than pre-hyperthermia in two cases (cervix 2 and 6, Figure
4(B)); (2) similar levels of BRCA2 in both biopsies in one case
(cervix 5, Figure 4(B)); and (3) considerably more (>2 fold)
BRCA2 in the post-hyperthermia biopsy in three cases (cervix
1, 3 and 4, Figure 4(B)).
In five of these tumours, the amount of material obtained
was sufficient to include an ex vivo hyperthermia treatment
on the same biopsy material taken before the clinical hyper-
thermia treatment, as a control for the effectivity of hyper-
thermia in vivo (Figure 4(B), indicated with 42 C). In contrast
to the cervix tumour samples presented in Figure 3(A), where
ex vivo hyperthermia triggered BRCA2 degradation in all
cases, the same treatment did not induce degradation of
BRCA2 in two tumours within this set (cervix 1 and 5, Figure
4(B)). However, importantly, we did observe that the increase
in BRCA2 found in the post-hyperthermia biopsies of cervix 1
and 3 did not occur in the controlled ex vivo hyperthermia,
and were therefore most probably not inherent to molecular
mechanism in the tumour itself.
Cervical tumors
Head and Neck
Bladder 
BRCA2
ORC2
42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C
42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C
42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C
42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C
42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C
42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C 42°C37°C
42°C37°C
%66%84
(A)
(B)
(C)
%8%16 %21%74
**
*
BRCA2
ORC2
79% %44%02 %03%95%27
BRCA2
ORC2
*
*
44% %62%42 34%14%
BRCA2
ORC2
59% 42% 33% 51%
*
*
105%
*
*
*
*
*
*
* *
BRCA2
ORC2
122% 49% 51% 50% 91%
*
* * * *
BRCA2
ORC2
70% %61%72%84%97
Figure 3. BRCA2 degradation in tumours heated ex vivo. Immunoblots of (A) 11 cervical tumours, (B) five head and neck tumours, and (C) 16 bladder tumours.
Each pair of samples represents the non-hyperthermia-treated and treated samples of a tumour sample. ORC2 is shown as a loading control. Percentages at the bot-
tom of each panel indicate the relative intensity of the BRCA2 signal (corrected to ORC2) in the heat-treated sample compared to the non-treated sample. For clar-
ity of presentation, the shadow values were reset from 0 to 175 in Adobe Photoshop. PARP-1 is shown as a loading control and as an alternative to ORC2,
because the latter could not be detected in this sample.
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The variability in relative BRCA2 levels in the tumour
biopsy taken after hyperthermia treatment in vivo might be
explained by tumour heterogeneity, which would cause
inherent differences between the two biopsied parts of the
tumour. To test this possibility, we took biopsies (designated
biopsy A and B) from two macroscopically similar parts of
the same cervical tumour during an examination under
anaesthesia, and ex vivo incubated half of each biopsy at
37 C and the other half at 42 C. In both sample-sets, we
observed BRCA2 degradation to an equal extent upon heat.
However, the initial BRCA2-levels at 37 C were very different
(Figure 5). Theoretically, if biopsy B would have been the
biopsy taken before hyperthermia in vivo, and if biopsy A
was taken after hyperthermia, we would have found no dif-
ferences in BRCA2-levels, while BRCA2 was in fact degraded
by the heat treatment (Figure 5).
Discussion
Treatment with hyperthermia (41–42 C, 60min) induces deg-
radation of the BRCA2 protein in established cell lines, result-
ing in a temporary inhibition of the DNA repair pathway
homologous recombination (HR) [19]. This provides a pos-
sible explanation for hyperthermia’s sensitising effects
towards irradiation and chemotherapeutic compounds that
induce double strand breaks, such as cisplatin [34,35] and
Trabectedin [36]. Moreover, attenuation of HR by hyperther-
mia sensitises cultured cells and mouse tumours to PARP-
inhibitors [19,37–39], a class of therapeutics that specifically
target cells deficient in HR. PARP-inhibitors are currently
available as personalised treatment to patients with ovarian
cancer that harbour a BRCA-mutation and have relapsed after
initial platinum-containing treatment [27]. Via inhibition of
HR, mild hyperthermia has the potential to enlarge the group
of patients eligible for this treatment, especially because it
can be applied in a loco-regional fashion and is available to
treat a broad range of tumours [40].
In this study, we aimed to demonstrate that hyperthermia
induces degradation of BRCA2 not only in established cell
lines, but also in fresh, human tumours. We focussed on
tumour types that can be treated with hyperthermia in daily
practice: cervix, head and neck, bladder and breast. We first
show that BRCA2 is degraded upon heat (60min at 42 C) in
established cell lines of these tumour types. We then col-
lected cervix, head and neck and bladder tumours, and
tested BRCA2 protein degradation by shifting the tempera-
ture ex vivo from 37 C to 42 C for 60min. The BRCA2 pro-
tein levels after hyperthermia were lower than without
treatment in 11/11 cervical tumours in 4/5 of the head and
neck tumours and in 14/16 of the bladder tumours origin
(summarized in Figure S1), demonstrating that the molecular
pathways that mediate BRCA2-degradation upon heat are
functional in fresh tumour material, independent of its.
Our final aim was to determine whether BRCA2-
degradation could be used as a biomarker for efficiency of
clinical hyperthermia treatment. We investigated this by
obtaining two biopsies of the same breast tumour or cervical
tumour: one taken before and one taken after in vivo hyper-
thermia treatment. Due to unforeseen technical problems
with the preparation of the material obtained in the breast
cancer study, we were unable to obtain interpretable results.
In the six cervical cancer patients included, we found unex-
pected variation in the BRCA2-levels in the biopsy taken after
clinically applied hyperthermia relative to the levels in the
biopsies taken before hyperthermia.
The possibility that thermal doses reached in the clinical
setting are not sufficient to induce BRCA2 degradation does
not explain the observed increase in BRCA2 protein levels
after hyperthermia. However, there are several other factors
that could contribute to the variability in relative BRCA2-levels
(A)
(B)
Breast 1 Breast 2
BRCA2
ORC2
BRCA2
ORC2
BRCA2
ORC2
pre postpre post
Cervix 1
381% 108%
pre post 42 °C
21% 37%
Cervix 2
pre post 42 °C
408% 36%
Cervix 3
pre post 42 °C
262%
Cervix 4
pre post
Cervix 5
88% 125%
pre post42 °C
Cervix 6
43% 21%
*
*
pre post42 °C
*
*
BRCA2
ORC2
Figure 4. BRCA2 protein levels in biopsies taken before and after hyperthermia
treatment in vivo. Immunoblots of biopsies taken before (pre) and after (post)
hyperthermia in (A) breast tumours and in (B) cervical tumours. Samples marked
with “42 C” received ex vivo hyperthermia as an internal control. Shown are
BRCA2 and ORC2. The percentages at the bottom of each panel indicate the
relative intensity of the BRCA2 signal (corrected to ORC2) in the heat-treated
sample compared to the non-treated sample. For clarity of presentation the
shadow values were reset from 0 to 175 in Adobe Photoshop.
A B
51% 53%
42°C37°C 42°C37°C
BRCA2
ORC2
Figure 5. Tumour heterogeneity contributes to pre-hyperthermia protein levels
of BRCA2 in cervical tumours. Immunoblots of two biopsies (A and B) taken
from the same cervical tumour and treated ex vivo in the same hyperthermia-
session at 42 C. Upper panel shows the BRCA2-signal, the lower ORC2. The per-
centages at the bottom of the panel indicate the relative intensity of the BRCA2
signal (corrected to ORC2) in the heat-treated sample compared to the non-
treated sample for each biopsy.
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in tumour biopsies taken after hyperthermia treatment in vivo.
The first explanation is the inherent variability of BRCA2-pro-
tein levels in each biopsy, caused by intra-tumour heterogen-
eity (Figure 5), a feature which commonly occurs in cervical
tumours [41–43]. Differences in the cell cycle distribution
within a tumour part would influence the BRCA2 protein lev-
els, because its expression depends heavily on the cycling
state of the cells [44]. These inherent tumour differences
might be amplified by the fact that, in four of the six cases,
we opted to obtain the pre-hyperthermia biopsy up to a
month before the start of the treatment, in order to reduce
the burden on the patient (Figure 4(B), cervix 1, 2, 5 and 6).
Other biological events that may have contributed to the
increase in BRCA2 protein levels after hyperthermia are the
physiological effects of hyperthermia in vivo: the increased
blood flow and the immunological response upon heat could
introduce new cells to the tumour, in which the BRCA2 pro-
teins have not had a chance to be affected by heat [45].
Since the logistics in this study limited us to taking the
second biopsy approximately 45min after the end of hyper-
thermia, non-heated, non-tumour cells potentially could have
infiltrated the tumour after the end of treatment, clouding
the effects of hyperthermia on BRCA2.
The results obtained in the studies that examine the
effects of clinically applied hyperthermia on BRCA2, demon-
strate that no valid conclusions can be drawn when compar-
ing immunoblot signals resulting from two separate biopsies.
In a clinical setting, the BRCA2-signal in a first biopsy can
therefore not be used as a control for the BRCA2-signal in
the biopsy taken after hyperthermia. However, the results do
imply that an experimental approach where a tumour biopsy
is taken before hyperthermia and another one after could be
a valuable method to identify differences in the cell popula-
tions in the biopsies upon hyperthermia, elucidating physio-
logical or immunological mechanisms of hyperthermia.
In this study we aimed to explore hyperthermia’s ability to
degrade BRCA2 in freshly biopsied tumour material. We have
indeed demonstrated that heat-induced BRCA2 degradation
is not limited to established cell lines, but is also applicable
to tumours heated ex vivo. We also explored whether BRCA2-
degradation could be a feasible biomarker for determining
effectivity of heat deposition by clinically applied hyperther-
mia, but found that this is not the case: due to technical diffi-
culties in dissociation of some tumours and intra-tumour
heterogeneity, it was not possible to accurately determine
BRCA2-levels after hyperthermia in vivo. However, the results
of this study indicate that hyperthermia is an effective
method to create a local environment of HR-deficiency in
tumours, and could indeed provide a rational basis to
increase the group of patients that could potentially benefit
from PARP-inhibitors.
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